RRC ID 39944
Author Yamamoto Y, Nakajima M, Yamazaki H, Yokoi T.
Title Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Journal Life Sci
Abstract Troglitazone is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus. It has been reported that troglitazone causes severe hepatic injury in certain individuals. In the present study, the mechanism for the hepatic injury by troglitazone was investigated with human hepatoma cell lines. HepG2 cells were incubated with troglitazone, its metabolites M-1 (sulfate), M-2 (gulucronide), M-3 (quinone), and other thiazolidinediones (pioglitazone and rosiglitazone). Troglitazone exhibited time- and concentration-dependent cytotoxicity and M-3 also exhibited weak cytotoxicity. Troglitazone induced apoptotic cell death characterized by internucleosomal DNA fragmentation and nuclear condensation. As other thiazolidinediones, pioglitazone and rosiglitazone, did not induce cell death and apoptosis in the present study, the affinity to PPARgamma may not affect the induction of apoptosis by troglitazone. These results suggest that troglitazone induces apoptotic hepatocyte death which it may be one of the factors of liver injury in humans.
Volume 70(4)
Pages 471-82
Published 2001-12-14
DOI 10.1016/s0024-3205(01)01432-1
PII S0024-3205(01)01432-1
PMID 11798015
MeSH Apoptosis / drug effects* Carcinoma, Hepatocellular Cell Survival / drug effects Chromans / metabolism Chromans / toxicity* DNA Fragmentation Dose-Response Relationship, Drug Humans Hypoglycemic Agents / metabolism Hypoglycemic Agents / toxicity* Pioglitazone Rosiglitazone Tetrazolium Salts / metabolism Thiazoles / metabolism Thiazoles / toxicity* Thiazolidinediones* Troglitazone Tumor Cells, Cultured / drug effects Tumor Cells, Cultured / metabolism Tumor Cells, Cultured / pathology
IF 3.647
Times Cited 74
WOS Category PHARMACOLOGY & PHARMACY MEDICINE, RESEARCH & EXPERIMENTAL
Resource
Human and Animal Cells HuH-7(RCB1366)